Recent advances in understanding/managing type 2 diabetes mellitus.

about

Recent advances in understanding/managing type 2 diabetes mellitus.

Item

http://www.wikidata.org/entity/Q47161786

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Recent advances in understanding/managing type 2 diabetes mellitus.

@en

Recent advances in understanding/managing type 2 diabetes mellitus.

@nl

type

Item

label

Recent advances in understanding/managing type 2 diabetes mellitus.

@en

Recent advances in understanding/managing type 2 diabetes mellitus.

@nl

prefLabel

Recent advances in understanding/managing type 2 diabetes mellitus.

@en

Recent advances in understanding/managing type 2 diabetes mellitus.

@nl

P1476

Recent advances in understanding/managing type 2 diabetes mellitus.

@en

P2860

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Biologic Responses to Weight Loss and Weight Regain: Report From an American Diabetes Association Research Symposium

Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects

Association of an intensive lifestyle intervention with remission of type 2 diabetes.

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans

P31

scholarly article

P356

10.12688/F1000RESEARCH.11192.1

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Pablo Aschner

P577

2017-10-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29152218

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

5664973

http://www.w3.org/2001/XMLSchema#string